Pharmaceuticals News and Research

RSS

Procter & Gamble reports net sales of $19.8 billion for the July - September quarter

The Procter & Gamble Company (NYSE: PG) reported net sales of $19.8 billion for the July - September quarter which exceeded the Company's guidance.

29 Oct 2009

Interim safety review of LEVADEX completed by MAP Pharmaceuticals

MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.

29 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

Activaero announces closing of a € 10.7M Series A financing

Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled therapeutic agents, announced today the closing of a Series A financing totalling € 10.7 Million ($16 million). The international consortium was led by BioMedPartners AG (advising BioMedInvest LP II) and included VI Partners AG, Abalis Finance AG and Vesalius Biocapital I SICAR S.A.. The transaction was advised by MedVenture Partners GmbH.

29 Oct 2009

Bio-Pharmaceutical Summit 2009 to be held in China

Biotechnology is an emerging industry to which many countries are attaching great importance. China is determined to grasp the great opportunities brought by the biotechnology revolution. Biotech industry will become a pillar of China’s hi-tech sector, in which bio-pharmaceutical is playing a leading role.

29 Oct 2009

Winning placement on Managed Care formularies, the first step for product's increased market share

In today's payer-driven pharmaceutical marketplace, winning placement on Managed Care formularies marks only the first step for a product's increased market share. However 90 percent of executives working in Managed Care rate pull through tactics, such as health fairs and formulary update letters, as effective ways to impact demand after formulary placement.

29 Oct 2009

AAPS workshop on drug release methodologies

AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.

29 Oct 2009

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

29 Oct 2009

Report on marketing the bio-pharmaceutical products released

The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.

29 Oct 2009

FDA issues a Complete Response Letter regarding NDA for Intermezzo

Transcept Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet).

29 Oct 2009

Cempra Pharmaceuticals stages a presentation on CEM-101

Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

29 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

InfoMedics launches doctor-patient feedback programs

InfoMedics, Inc. has implemented patient feedback programs to improve doctor-patient communication and enhance the impact of marketing programs for biopharmaceutical brands through every phase and challenge of the product life cycle: disease state awareness, early experience, branded launch campaign, growth, mature product and patient compliance.

29 Oct 2009

Dysport drug for treatment of cervical dystonia launched in the United States

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that Dysport® is now available in the United States for the treatment of cervical dystonia in adults.

29 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

BioMed Realty Trust reports increased revenues of $93.0 million for the third quarter

BioMed Realty Trust, Inc., a real estate investment trust focused on Providing Real Estate to the Life Science Industry®, today announced operating and financial results for the third quarter ended September 30, 2009.

29 Oct 2009

LabelDataPlus online drug label database launched by Reed Technology and Information Services

Reed Technology and Information Services Inc., a LexisNexis® business, today announced the introduction of LabelDataPlus™ – a comprehensive drug label database available on the Web for both industry and consumer use. LabelDataPlus offers more than 5,000 current and archived FDA-approved drug labels – the same drug information found on the National Library of Medicine’s DailyMed web site – combined with powerful search features that unlock the information contained in drug labels (package inserts).

28 Oct 2009